Skip to content
Products & Services · Product revenues, net

ALYFTREK — Product revenues, net

Vertex Pharmaceuticals ALYFTREK — Product revenues, net increased by 11.7% to $424.4M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 687.4%, from $53.9M to $424.4M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026May 5, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates growing market penetration and patient adoption, while a decrease may signal competitive pressure, patent expiration, or market saturation.

Detailed definition

This metric represents the total net sales generated from the specific pharmaceutical product or therapeutic line after...

Peer comparison

Comparable to net product sales reported by other biotechnology and pharmaceutical companies for specific branded therapies or drug franchises.

Metric ID: vrtx_segment_alyftrek_product_revenues_net

Historical Data

13 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0$0$0$0$0$0$0$0$53.9M$156.8M$247M$380.1M$424.4M
QoQ Change+190.9%+57.5%+53.9%+11.7%
YoY Change+687.4%
Range$0$424.4M
Avg YoY Growth+687.4%
Median YoY Growth+687.4%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's alyftrek — product revenues, net?
Vertex Pharmaceuticals (VRTX) reported alyftrek — product revenues, net of $424.4M in Q1 2026.
How has Vertex Pharmaceuticals's alyftrek — product revenues, net changed year-over-year?
Vertex Pharmaceuticals's alyftrek — product revenues, net increased by 687.4% year-over-year, from $53.9M to $424.4M.
What does alyftrek — product revenues, net mean?
The total net sales revenue generated by a specific pharmaceutical product or therapeutic line.